New hope for transplant patients with Treatment-Resistant complications
NCT ID NCT01688466
Summary
This study tested whether the drug pomalidomide could help control chronic graft-versus-host disease (GvHD) in people who didn't respond to standard steroid treatments. GvHD is a serious complication that can occur after a stem cell transplant, where the donor's immune cells attack the recipient's body. The trial involved 34 adults with moderate to severe GvHD who took pomalidomide daily for up to six months to see if it could improve their condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS. HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.